An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo

Medicine & Life Sciences

• SF 1126 100%
• Phosphoinositide-3 Kinase Inhibitors 64%
• Multiple Myeloma 45%
• Integrins 43%
• Protein Isoforms 36%
• Bortezomib 24%
• Clinical Trials, Phase I 12%
• Hematologic Neoplasms 10%
• Neoplasms 9%
• In Vitro Techniques 6%
• Proteasome Inhibitors 6%
• Cell Line 6%
• Proliferating Cell Nuclear Antigen 5%
• Phosphatidylinositol 3-Kinase 5%
• Insulin-Like Growth Factor I 5%
• Growth 5%
• Microvessels 5%
• Nude Mice 4%
• Heterografts 4%
• Signal Transduction 3%
• Cell Proliferation 3%
• Survival 2%
• Therapeutics 1%

Chemical Compounds

• Phosphatidylinositol 3 Kinase Inhibitor 78%
• Bortezomib 76%
• Phosphotransferase Inhibitor 38%
• Antitumor 28%
• Proteasome Inhibitor 22%
• Block Like Crystal 10%